Developer docs
API playgroundTry for free, no card

Search company profiles

NS Pharma

Full company profile

uuid0006678

Namestring
NS Pharma
Legal namestring
NS Pharma, Inc.
Websiteurl
nspharma.com
Company typeenum
Private
Founded yearint
1999
Descriptiontext

NS Pharma, Inc. is a U.S.-based, wholly-owned subsidiary of Nippon Shinyaku Co., Ltd., a Japanese pharmaceutical company headquartered in Kyoto with over a century of history. The company is headquartered at 140 East Ridgewood Avenue in Paramus, New Jersey, with a secondary Innovation Research Partnering office in Cambridge, Massachusetts, and operates with 51-100 employees. NS Pharma focuses exclusively on rare diseases with high unmet medical need, spanning Duchenne muscular dystrophy (DMD), Hunter syndrome (MPS II), and eosinophilic granulomatosis with polyangiitis (EGPA).

The company's portfolio rests on three proprietary technology platforms: exon-skipping antisense oligonucleotides (producing dystrophin proteins 84-97% as long as the full-length protein for common DMD mutations), gene therapy (via NAVSUNLI/RGX-121 for MPS II and ATSN-101 for LCA1), and selective JAK1 inhibition (NS-229 for EGPA). Its single commercial product is VILTEPSO (viltolarsen), an exon 53-skipping therapy that received FDA accelerated approval in August 2020 for DMD. The pipeline includes deramiocel (CAP-1002) for DMD cardiomyopathy with a PDUFA target date of August 22, 2026; NAVSUNLI (clemidsogene lanparvovec) for MPS II under BLA review; brogidirsen (NS-089/NCNP-02) for exon 44 skipping with 4.5-year clinical data; NS-229 in Phase 2 for EGPA; and earlier-stage programs including NS-050/NCNP-03, NS-051/NCNP-04, RGX-111, EXG-7001, and RNAa programs with MiNA Therapeutics.

NS Pharma generates revenue primarily through direct U.S. commercialization of VILTEPSO via its own specialty field sales force targeting neurologists and rare disease treatment centers, supplemented by licensing and royalty arrangements on partnered products. The company holds exclusive U.S. commercialization rights for deramiocel (under a 2022 agreement with Capricor Therapeutics), NAVSUNLI (under a January 2025 agreement with REGENXBIO), and ATSN-101 (with Atsena Therapeutics). It also maintains patient support services (NS Support), market access infrastructure, and a network of patient advocacy partnerships (CureDuchenne, PPMD, MDA, Jett Foundation, etc.). Revenue figures are not publicly disclosed.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersParamus, United States
HQ citystring
Paramus
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, exon-skipping therapies, orphan drug development, gene therapy medicines, cell therapy products
Industry5 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Rare Disease Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

NS Pharma generates revenue from the sale of Viltepso (viltolarsen), an FDA-approved exon-skipping therapy for DMD. The company commercializes the product directly in the U.S. market through its commercial infrastructure.

2Partnership Revenue (REGENXBIO/NAVSUNLI)
TypeLicensing Royalties
Description

Under a January 2025 partnership, NS Pharma holds U.S. commercialization rights for NAVSUNLI (clemidsogene lanparvovec), a gene therapy for MPS II. NS Pharma will commercialize the therapy upon FDA approval.

stocktitan.net
3Partnership Revenue (Capricor/deramiocel)
TypeLicensing Royalties
Description

NS Pharma holds exclusive U.S. commercialization rights for deramiocel (CAP-1002), a cell therapy for DMD cardiomyopathy, under an agreement with Capricor Therapeutics.

Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1VILTEPSO (viltolarsen)
Description

FDA-approved exon-skipping therapy for Duchenne muscular dystrophy patients with confirmed mutation amenable to exon 53 skipping.

+3 more records
Core offering1 text field

NS Pharma is a commercial-stage biopharmaceutical company that develops, manufactures, and commercializes therapies for rare diseases, with a primary focus on Duchenne muscular dystrophy (DMD), Hunter syndrome (MPS II), and eosinophilic granulomatosis with polyangiitis (EGPA). Its marketed product is VILTEPSO (viltolarsen), an FDA-approved exon 53 skipping antisense oligonucleotide for DMD, and its pipeline includes additional exon-skipping therapies, gene therapies, a cell therapy, and a selective JAK1 inhibitor.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Exon-skipping therapy produces dystrophin 84-97% as long as full-length protein for common mutations
+4 more records
Product overview1 text field

NS Pharma is a biopharmaceutical company focused on rare diseases, developing a portfolio of therapies across multiple technology platforms. The company operates as a subsidiary of Nippon Shinyaku Co., Ltd. The product portfolio includes: VILTEPSO (viltolarsen), an FDA-approved exon 53 skipping therapy for DMD; Deramiocel (CAP-1002), a cell therapy for DMD cardiomyopathy under FDA review; RGX-121, a gene therapy for MPS II under FDA review; and multiple pipeline candidates including brogidirsen (exon 44 skipping), NS-229 (JAK1 inhibitor for EGPA), NS-050/NCNP-03 (exon 50 skipping), ATSN-101 (gene therapy for LCA1), RGX-111 (gene therapy for MPS I), NS-051/NCNP-04 (exon 51 skipping), and EXG-7001 (mRNA therapy for DMD). Scientific approaches include exon-skipping technology, gene therapy, cell therapy, and selective JAK1 inhibition.

Product and service3 records
1VILTEPSO (viltolarsen)
CategoryDMD exon-skipping therapy
Description

VILTEPSO is an FDA-approved exon-skipping antisense oligonucleotide therapy for Duchenne muscular dystrophy (DMD) patients with confirmed mutations amenable to exon 53 skipping, designed to enable production of a shortened but functional dystrophin protein.

2Deramiocel (CAP-1002)
CategoryDMD cell therapy
Description

Deramiocel is an investigational allogeneic cardiosphere-derived cell (CDC) therapy for Duchenne muscular dystrophy cardiomyopathy, being developed with Capricor Therapeutics and under FDA BLA review with a PDUFA target date of August 22, 2026.

3NAVSUNLI / RGX-121 (clemidisogene lanparvovec)
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-26
Description

Nippon Shinyaku (NS Pharma parent) entered an option agreement with Elixirgen Therapeutics to obtain exclusive worldwide rights to develop and commercialize EXG-7001, an investigational mRNA-based therapeutic for DMD. EXG-7001 is in preclinical development and expresses full-length human dystrophin protein. NS Pharma intends to commercialize EXG-7001 in the U.S. following option exercise and regulatory approval.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

Nippon Shinyaku entered a Sponsored Research Agreement with Boston Children's Hospital to develop innovative therapeutic drugs in neurology. The collaboration builds on a strategic alliance initiated in July 2025 and aims to combine Boston Children's Hospital's research capabilities with Nippon Shinyaku's drug discovery expertise. Facilitated by NS Pharma's Innovation Research Partnering team in Cambridge, MA.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Under a January 2025 partnership, NS Pharma holds U.S. commercialization rights for NAVSUNLI (clemidsogene lanparvovec-sngl), an investigational gene therapy for Mucopolysaccharidosis II (MPS II/Hunter syndrome). REGENXBIO is responsible for development and BLA submission; NS Pharma commercializes in the U.S. upon approval. Target approximately 2,000 MPS II patients worldwide.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-01
Description

Nippon Shinyaku entered a joint research agreement with MiNA Therapeutics to develop small activating RNAs (saRNAs) using RNA activation (RNAa) technology to treat rare and intractable diseases of the central nervous system. MiNA is the world leader in RNAa drugs. Initial target is a severe neurodevelopmental disorder caused by a single defective gene affecting hundreds of thousands worldwide with no approved treatments.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Nippon Shinyaku and Capricor entered an exclusive distribution agreement for deramiocel (CAP-1002) for the U.S. in January 2022. NS Pharma is exclusively responsible for commercialization and distribution of deramiocel in the U.S. Deramiocel is a cell therapy for DMD cardiomyopathy with PDUFA target date of August 22, 2026. Note: A breach-of-contract lawsuit was filed by Capricor against NS Pharma and Nippon Shinyaku in 2026.

6National Center of Neurology and Psychiatry (NCNP)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

NCNP co-discovered brogidirsen (NS-089/NCNP-02) with Nippon Shinyaku. NCNP conducted investigator-initiated Phase 1/2 clinical trial; Nippon Shinyaku conducted extension study. Ongoing collaboration on DMD exon 44 skipping therapy.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Nippon Shinyaku partners with Atsena Therapeutics for gene therapy development targeting GUCY2D-associated Leber congenital amaurosis (LCA1). Atsena is responsible for progress and development of this program.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Patient advocacy organization partnership for Duchenne muscular dystrophy awareness and support.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Patient advocacy organization partnership for Duchenne muscular dystrophy. PPMD partnered with CINRG to support expanded Duchenne Natural History Study.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Patient advocacy organization partnership. NS Pharma presents clinical data at MDA Clinical & Scientific Conference.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NS Pharma

Rare Disease Biopharmaceuticalsnspharma.com

What NS Pharma does

NS Pharma, Inc. is a U.S.-based, wholly-owned subsidiary of Nippon Shinyaku Co., Ltd., a Japanese pharmaceutical company headquartered in Kyoto with over a century of history. The company is headquartered at 140 East Ridgewood Avenue in Paramus, New Jersey, with a secondary Innovation Research Partnering office in Cambridge, Massachusetts, and operates with 51-100 employees. NS Pharma focuses exclusively on rare diseases with high unmet medical need, spanning Duchenne muscular dystrophy (DMD), Hunter syndrome (MPS II), and eosinophilic granulomatosis with polyangiitis (EGPA).

The company's portfolio rests on three proprietary technology platforms: exon-skipping antisense oligonucleotides (producing dystrophin proteins 84-97% as long as the full-length protein for common DMD mutations), gene therapy (via NAVSUNLI/RGX-121 for MPS II and ATSN-101 for LCA1), and selective JAK1 inhibition (NS-229 for EGPA). Its single commercial product is VILTEPSO (viltolarsen), an exon 53-skipping therapy that received FDA accelerated approval in August 2020 for DMD. The pipeline includes deramiocel (CAP-1002) for DMD cardiomyopathy with a PDUFA target date of August 22, 2026; NAVSUNLI (clemidsogene lanparvovec) for MPS II under BLA review; brogidirsen (NS-089/NCNP-02) for exon 44 skipping with 4.5-year clinical data; NS-229 in Phase 2 for EGPA; and earlier-stage programs including NS-050/NCNP-03, NS-051/NCNP-04, RGX-111, EXG-7001, and RNAa programs with MiNA Therapeutics.

NS Pharma generates revenue primarily through direct U.S. commercialization of VILTEPSO via its own specialty field sales force targeting neurologists and rare disease treatment centers, supplemented by licensing and royalty arrangements on partnered products. The company holds exclusive U.S. commercialization rights for deramiocel (under a 2022 agreement with Capricor Therapeutics), NAVSUNLI (under a January 2025 agreement with REGENXBIO), and ATSN-101 (with Atsena Therapeutics). It also maintains patient support services (NS Support), market access infrastructure, and a network of patient advocacy partnerships (CureDuchenne, PPMD, MDA, Jett Foundation, etc.). Revenue figures are not publicly disclosed.

NS Pharma firmographics

Firmographics
Name
NS Pharma
Legal name
NS Pharma, Inc.
Website
https://nspharma.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

NS Pharma industry classification

Industry
Product category
Rare Disease Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Rare disease therapeutics
  • Exon-skipping therapies
  • Orphan drug development
  • Gene therapy medicines
  • Cell therapy products

Where NS Pharma is headquartered

Location

Headquarters

HQ city
Paramus
HQ country
United States
HQ region
North America

Offices2 records

Markets served

NS Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical Product Sales: NS Pharma generates revenue from the sale of Viltepso (viltolarsen), an FDA-approved exon-skipping therapy for DMD. The company commercializes the product directly in the U.S. market through its commercial infrastructure.
  2. Partnership Revenue (REGENXBIO/NAVSUNLI): Under a January 2025 partnership, NS Pharma holds U.S. commercialization rights for NAVSUNLI (clemidsogene lanparvovec), a gene therapy for MPS II. NS Pharma will commercialize the therapy upon FDA approval.
  3. Partnership Revenue (Capricor/deramiocel): NS Pharma holds exclusive U.S. commercialization rights for deramiocel (CAP-1002), a cell therapy for DMD cardiomyopathy, under an agreement with Capricor Therapeutics.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

NS Pharma product offering

Product offering

Core offering

NS Pharma is a commercial-stage biopharmaceutical company that develops, manufactures, and commercializes therapies for rare diseases, with a primary focus on Duchenne muscular dystrophy (DMD), Hunter syndrome (MPS II), and eosinophilic granulomatosis with polyangiitis (EGPA). Its marketed product is VILTEPSO (viltolarsen), an FDA-approved exon 53 skipping antisense oligonucleotide for DMD, and its pipeline includes additional exon-skipping therapies, gene therapies, a cell therapy, and a selective JAK1 inhibitor.

Product overview

NS Pharma is a biopharmaceutical company focused on rare diseases, developing a portfolio of therapies across multiple technology platforms. The company operates as a subsidiary of Nippon Shinyaku Co., Ltd. The product portfolio includes: VILTEPSO (viltolarsen), an FDA-approved exon 53 skipping therapy for DMD; Deramiocel (CAP-1002), a cell therapy for DMD cardiomyopathy under FDA review; RGX-121, a gene therapy for MPS II under FDA review; and multiple pipeline candidates including brogidirsen (exon 44 skipping), NS-229 (JAK1 inhibitor for EGPA), NS-050/NCNP-03 (exon 50 skipping), ATSN-101 (gene therapy for LCA1), RGX-111 (gene therapy for MPS I), NS-051/NCNP-04 (exon 51 skipping), and EXG-7001 (mRNA therapy for DMD). Scientific approaches include exon-skipping technology, gene therapy, cell therapy, and selective JAK1 inhibition.

Differentiator

Problem solved

Functional benefit

Brands

  • VILTEPSO (viltolarsen): FDA-approved exon-skipping therapy for Duchenne muscular dystrophy patients with confirmed mutation amenable to exon 53 skipping.
  • We Speak Duchenne
  • NS Support
  • Viltepso

Products and services

  • VILTEPSO (viltolarsen) VILTEPSO is an FDA-approved exon-skipping antisense oligonucleotide therapy for Duchenne muscular dystrophy (DMD) patients with confirmed mutations amenable to exon 53 skipping, designed to enable production of a shortened but functional dystrophin protein.
  • Deramiocel (CAP-1002) Deramiocel is an investigational allogeneic cardiosphere-derived cell (CDC) therapy for Duchenne muscular dystrophy cardiomyopathy, being developed with Capricor Therapeutics and under FDA BLA review with a PDUFA target date of August 22, 2026.
  • NAVSUNLI / RGX-121 (clemidisogene lanparvovec)

Quantifiable outcome

  • Exon-skipping therapy produces dystrophin 84-97% as long as full-length protein for common mutations
  • +4 more outcomes

Companies that use NS Pharma

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

NS Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

NS Pharma partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered minor and core.

  • Elixirgen TherapeuticsminorStrategic or Co-development Partner · 26 June 2026Nippon Shinyaku (NS Pharma parent) entered an option agreement with Elixirgen Therapeutics to obtain exclusive worldwide rights to develop and commercialize EXG-7001, an investigational mRNA-based therapeutic for DMD. EXG-7001 is in preclinical development and expresses full-length human dystrophin protein. NS Pharma intends to commercialize EXG-7001 in the U.S. following option exercise and regulatory approval.
  • Boston Children's HospitalcoreStrategic or Co-development Partner · 23 June 2026Nippon Shinyaku entered a Sponsored Research Agreement with Boston Children's Hospital to develop innovative therapeutic drugs in neurology. The collaboration builds on a strategic alliance initiated in July 2025 and aims to combine Boston Children's Hospital's research capabilities with Nippon Shinyaku's drug discovery expertise. Facilitated by NS Pharma's Innovation Research Partnering team in Cambridge, MA.
  • REGENXBIO Inc.coreStrategic or Co-development Partner · 1 January 2025Under a January 2025 partnership, NS Pharma holds U.S. commercialization rights for NAVSUNLI (clemidsogene lanparvovec-sngl), an investigational gene therapy for Mucopolysaccharidosis II (MPS II/Hunter syndrome). REGENXBIO is responsible for development and BLA submission; NS Pharma commercializes in the U.S. upon approval. Target approximately 2,000 MPS II patients worldwide.
  • MiNA TherapeuticscoreStrategic or Co-development Partner · 1 April 2024Nippon Shinyaku entered a joint research agreement with MiNA Therapeutics to develop small activating RNAs (saRNAs) using RNA activation (RNAa) technology to treat rare and intractable diseases of the central nervous system. MiNA is the world leader in RNAa drugs. Initial target is a severe neurodevelopmental disorder caused by a single defective gene affecting hundreds of thousands worldwide with no approved treatments.
  • Capricor TherapeuticscoreStrategic or Co-development Partner · 1 January 2022Nippon Shinyaku and Capricor entered an exclusive distribution agreement for deramiocel (CAP-1002) for the U.S. in January 2022. NS Pharma is exclusively responsible for commercialization and distribution of deramiocel in the U.S. Deramiocel is a cell therapy for DMD cardiomyopathy with PDUFA target date of August 22, 2026. Note: A breach-of-contract lawsuit was filed by Capricor against NS Pharma and Nippon Shinyaku in 2026.
  • National Center of Neurology and Psychiatry (NCNP)coreStrategic or Co-development PartnerNCNP co-discovered brogidirsen (NS-089/NCNP-02) with Nippon Shinyaku. NCNP conducted investigator-initiated Phase 1/2 clinical trial; Nippon Shinyaku conducted extension study. Ongoing collaboration on DMD exon 44 skipping therapy.
  • Atsena TherapeuticsminorStrategic or Co-development PartnerNippon Shinyaku partners with Atsena Therapeutics for gene therapy development targeting GUCY2D-associated Leber congenital amaurosis (LCA1). Atsena is responsible for progress and development of this program.
  • CureDuchenneminorGTM or Marketing PartnerPatient advocacy organization partnership for Duchenne muscular dystrophy awareness and support.
  • Parent Project Muscular Dystrophy (PPMD)minorGTM or Marketing PartnerPatient advocacy organization partnership for Duchenne muscular dystrophy. PPMD partnered with CINRG to support expanded Duchenne Natural History Study.
  • Muscular Dystrophy Association (MDA)minorGTM or Marketing PartnerPatient advocacy organization partnership. NS Pharma presents clinical data at MDA Clinical & Scientific Conference.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

NS Pharma competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key highlights6 records

Customer concentration

NS Pharma social profiles

Digital presence

NS Pharma compliance and trust

Trust signal

Compliance3 records

NS Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NS Pharma leadership team

Management profile

Number of profiles

Profiles13 records

NS Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NS Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NS Pharma

What does NS Pharma do?

NS Pharma is a commercial-stage biopharmaceutical company that develops, manufactures, and commercializes therapies for rare diseases, with a primary focus on Duchenne muscular dystrophy (DMD), Hunter syndrome (MPS II), and eosinophilic granulomatosis with polyangiitis (EGPA). Its marketed product is VILTEPSO (viltolarsen), an FDA-approved exon 53 skipping antisense oligonucleotide for DMD, and its pipeline includes additional exon-skipping therapies, gene therapies, a cell therapy, and a selective JAK1 inhibitor.

Is NS Pharma a public or private company?

NS Pharma is a private company. It is classified as corporate owned and is currently operating.

When was NS Pharma founded?

NS Pharma was founded in 1999. It employs 101 to 250 people.

Where is NS Pharma based?

NS Pharma is headquartered in Paramus, United States, in the North America region.

How does NS Pharma make money?

Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are partnership Revenue (REGENXBIO/NAVSUNLI) and partnership Revenue (Capricor/deramiocel).

Does NS Pharma have an API?

No public API is recorded for NS Pharma.

What industry is NS Pharma in?

NS Pharma's product category is Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
StocktwitsCAPR Stock Rallies After-Hours As Capricor Reaffirms Deramiocel Confidence Ahead Of Nov. 22 Decision; Says Application In Final ReviewCapricor Therapeutics reaffirmed confidence in its deramiocel therapy for Duchenne muscular dystrophy, with the FDA set to decide by November 22. The company's Biologics License Application is in final review, and the stock rose 5% after hours. Capricor continues independent commercialization amid arbitration with NS Pharma.The Motley FoolCapricor (CAPR) Q2 2026 Earnings Call TranscriptCapricor Therapeutics reported a net loss of $40.7 million for the second quarter of 2026 and announced plans to amend its Biologics License Application for Deramiocel following an FDA Advisory Committee vote against its cardiomyopathy indication. The company will pivot its regulatory strategy to focus on an upper limb skeletal muscle indication, supported by statistically significant Phase 3 data, while initiating arbitration against distribution partner NS Pharma. Management has placed non-core pipeline programs on hold and is pacing commercial expenditures to preserve its cash runway.The Motley FoolCapricor (CAPR) Q2 2026 Earnings Call TranscriptCapricor Therapeutics reported a widened net loss for Q2 2026 as it pivots its regulatory strategy for Deramiocel following an FDA Advisory Committee vote against its cardiomyopathy indication. The company plans to submit a BLA amendment focusing on upper limb skeletal muscle function, supported by positive Phase 3 data, while initiating arbitration against distributor NS Pharma over contract disputes.AInvestCAPR: The Insider Sale Story Is a Distraction. Here's What Actually Matters.Capricor Therapeutics stock declined 35% ahead of three overlapping binary catalysts that converge in the next four weeks: an FDA AdCom meeting on July 29 reviewing its deramiocel BLA for Duchenne muscular dystrophy cardiomyopathy, an August 10 New Jersey court hearing on Capricor's lawsuit to rescind its US commercialization agreement with NS Pharma, and an August 22 PDUFA decision date. The article argues the selloff is overdone given strong HOPE-3 Phase 3 trial data (met primary and secondary endpoints with p=0.03 and p=0.04), a $278.6M cash position providing runway through Q4 2027, GMP manufacturing facility cleared by FDA inspection, and analyst price targets of $51-$63 versus the current $19.70 share price.GlobeNewswireElixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular DystrophyElixirgen Therapeutics entered an option agreement with Nippon Shinyaku to develop EXG-7001 for Duchenne Muscular Dystrophy, with Nippon Shinyaku funding development and receiving exclusive worldwide commercialization rights. Elixirgen will get an upfront payment and milestone payments if the option is exercised.PR NewswireNS Pharma Parent Company, Nippon Shinyaku, Announces Sponsored Research Agreement with Boston Children's HospitalNippon Shinyaku Co., Ltd. has entered into a Sponsored Research Agreement with Boston Children's Hospital to develop innovative therapeutic drugs in the field of neurology. The agreement builds on a strategic collaboration initiated in July 2025 and aims to combine Boston Children's Hospital's research capabilities with Nippon Shinyaku's drug discovery expertise to accelerate new neurologic treatments for patients with unmet medical needs. The collaboration was facilitated by NS Pharma's Innovation Research Partnering team located in Cambridge, Massachusetts.The Pharma LetterCapricor sues over alleged NS Pharma inaction on deramiocelCapricor Therapeutics filed a lawsuit against Nippon Shinyaku and its US subsidiary NS Pharma over their US distribution agreement for deramiocel, an investigational cell therapy for Duchenne muscular dystrophy. The suit concerns the parties' agreement for the drug's distribution in the United States.STATThe biotech news you need to read todayCapricor Therapeutics has filed a lawsuit against its Japanese partner Nippon Shinyaku and subsidiary NS Pharma, alleging the companies botched launch preparations for deramiocel, their Duchenne muscular dystrophy cell therapy. The biotech firm also claims the defendants created a pricing structure that could make the treatment financially inaccessible for many patients. This legal dispute threatens to delay or disrupt the commercial launch of a closely watched therapy for a rare, progressive neuromuscular disease.FiercePharmaCapricor Therapeutics files breach-of-contract lawsuit against US partner NS PharmaCapricor Therapeutics has filed a breach-of-contract lawsuit in New Jersey Superior Court against NS Pharma and its parent company Nippon Shinyaku, alleging that NS Pharma failed to adequately prepare for the commercial launch of their Duchenne muscular dystrophy treatment deramiocel and halted launch preparations after the FDA initially rejected the therapy. Capricor is seeking an injunction to restore its U.S. commercial rights, citing a pricing flaw in their commercialization agreement that the company says will prevent patients covered by Medicare, Medicaid, or private insurance from accessing the therapy. Following the lawsuit announcement, Capricor shares dropped 13% while Nippon Shinyaku shares fell 15%, with the FDA set to rule on deramiocel by August 22.BenzingaCapricor Therapeutics Says NS Pharma Delays Could Threaten Access To Duchenne Therapy - Capricor TherapeuCapricor Therapeutics Inc. filed a lawsuit against Nippon Shinyaku Co., Ltd. and its U.S. subsidiary NS Pharma, Inc. on Thursday, alleging that flaws in their U.S. distribution agreement for experimental Duchenne muscular dystrophy treatment Deramiocel would restrict patient access to the therapy. The dispute centers on pricing terms that Capricor claims would prevent patients covered by Medicare, Medicaid, and private insurance from obtaining the treatment. The FDA is currently reviewing Deramiocel with a target PDUFA action date of August 22, 2026.